BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

LifeVantage Corporation (LFVN) Announces Fiscal Year 2010 Financial and Operating Results


9/16/2010 11:42:19 AM

SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- LifeVantage Corporation (OTC Bulletin Board: LFVN), the maker of Protandim®, a patented dietary supplement that has been shown in a clinical trial to reduce the age-dependent increase in markers of oxidative stress, announced today fiscal year 2010 financial and operating results.

(Logo: http://photos.prnewswire.com/prnh/20090930/LIFEVANTAGELOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090930/LIFEVANTAGELOGO)

The Company recorded net revenues of $11.5 million and a net loss of ($11) million, or ($0.19) per share, for its year ended June 30, 2010. For its year ended June 30, 2009, the Company recorded net revenues of $4.1 million and a net loss of ($9.1) million or ($0.23) per share. The Company is also presenting selected unaudited quarterly financial data, to highlight the Company's progress in growing revenues while managing cost of goods and operating expenses.

"During the past fiscal year we have made significant progress under the network marketing model, seeing our net revenue increase by approximately 177% compared to our last fiscal year," stated David W. Brown, President & CEO. "All of our significant revenue markers, distributor enrollment, preferred customer enrollment, autoship orders, and spot revenues are up, as our distributor ranks grow and our strategy of identifying, training, and supporting distributor leaders as they build large, strong sales organizations appears to be working well."

"Our quarterly revenue increased from $1.9 million in Q1 to over $4.4 million in Q4, while we simultaneously reduced our total operating expenses from $4.6 million in Q1 to just under $4 million in Q4. This reduced our quarterly operating loss from over $3 million in Q1, compared to under $300 thousand in Q4," stated Carrie E. Carlander, CFO. "The funds raised in fiscal 2010 allowed us to rapidly grow our business, providing us a platform, as we enter fiscal year 2011, that we believe will enable us to begin generating sustainable cash flows and operating profits."

Conference Call Information

The Company will hold a conference call on September 21, 2010 at 1:30pm Pacific time (4:30pm Eastern time) to discuss fourth fiscal quarter 2010 financial and operating results and provide an update on its business. David W. Brown, President & Chief Executive Officer, is scheduled to lead the call and will be joined by Carrie E. Carlander, Chief Financial Officer.

The conference call may be accessed by dialing (877) 719-9788 for domestic callers and entering the pass code 4872029. The webcast will be available live via the Internet by accessing the Investors section of LifeVantage's website at http://www.lifevantage.com/investor-profile.aspx. Replays of the webcast will be available on LifeVantage's website for 30 days and a phone replay will be available through September 26th, 2010 by dialing 888-203-1112 and entering the pass code 4872029.

About Protandim®

Protandim® is a patented dietary supplement that has been shown in a clinical trial to reduce the age-dependent increase in markers of oxidative stress, and has also been shown to provide substantial benefits to combat the variety of negative health effects caused by oxidative stress. Under the Dietary Supplement Health and Education Act, Protandim® is considered a "dietary supplement". LifeVantage is not promoting the use of Protandim® for the prevention of cancer. Protandim® is not intended for the prevention, diagnosis, treatment, mitigation or cure of any disease. For more information about Protandim®, visit www.LifeVantage.com.

About LifeVantage Corporation

LifeVantage Corporation is a publicly traded (OTCBB: LFVN), dietary supplement company that seeks to enhance life through anti-aging and wellness products while creating business opportunities. Founded in 2003 and based in San Diego, CA, LifeVantage currently offers two products backed by science: Protandim®, a dietary supplement that combats oxidative stress, and LifeVantage TrueScience Anti-Aging Cream, a scientifically-based skin care product. For more information, visit www.LifeVantage.com.

Forward Looking Statements

Statements in this document, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and similar expressions generally identify these forward-looking statements. Forward-looking statements in this document include, among other things, statements regarding future operations and operating income. These statements are not guarantees of future performance and involve certain risks and uncertainties. Actual results could differ materially due to factors such as: the success of our network marketing sales channel; third party actions involving our network marketing sales channel; product liability claims; future laws that may hinder or prohibit the production or sale of our products; unfavorable publicity about our products or our industry; and other risk factors disclosed in our filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of this release and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations Contact:

Ioana C. Hone

(858) 312-8000 Ext. 4



LIFEVANTAGE CORPORATION AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS


For the years ended,


June 30, 2010


June 30, 2009

Sales, net

$ 11,478,460


$ 4,141,304

Cost of sales

1,905,992


852,804

Gross profit

9,572,468


3,288,500

Operating expenses:




Sales and marketing

8,481,496


4,107,768

General and administrative

7,765,331


6,588,414

Research and development

392,691


224,366

Depreciation and amortization

254,902


173,030

Total operating expenses

16,894,420


11,093,578

Operating (loss)

(7,321,952)


(7,805,078)

Other income and (expense):




Interest expense, net

(6,828,049)


(1,309,556)

Change in fair value of derivatives

3,101,673


-

Total other (expense) income

(3,726,376)


(1,309,556)

Net (loss)

$(11,048,328)


$ (9,114,634)

Net (loss) per share, basic and diluted

$ (0.19)


$ (0.23)

Weighted average shares outstanding, basic and diluted

57,373,483


40,360,592



The Notes included in the Form 10-K for the year ended June 30, 2010 are an integral part of these financial statements.

LIFEVANTAGE CORPORATION AND SUBSIDIARY

SELECTED FINANCIAL DATA (UNAUDITED)


For the quarters ended,


September 30, 2009


December 31, 2009


March 31, 2010


June 30, 2010

Sales, net

$ 1,857,997


$ 2,455,646


$ 2,723,807


$ 4,441,010

Cost of sales

312,974


411,824


447,797


733,397

Gross profit

1,545,023


2,043,822


2,276,010


3,707,613









Operating expenses:








Sales and marketing

2,012,166


1,962,590


1,877,073


2,629,667

General and administrative

2,381,156


2,548,891


1,618,591


1,216,693

Research and development

106,892


118,522


69,863


97,414

Depreciation and amortization

53,298


93,475


53,960


54,169

Total operating expenses

4,553,512


4,723,478


3,619,487


3,997,943

Operating (loss)

$ (3,008,489)


$ (2,679,656)


$ (1,343,477)


$ (290,330)




Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES